Pharma industry reports 61 deals worth $6.4 billion in June 2022, says GlobalData

The pharma industry reported 61 deals worth $6.4 billion as compared to the last 12-month average (June 2021 to May 2022) of 81 deals worth $14.8 billion, a GlobalData report has notified.

Bristol-Myers Squibb Co to acquire all the outstanding shares of Turning Point Therapeutics for $4.1 billion; Gurnet Point Capital and Patient Square Capital LP to acquire Radius Health Inc for approximately $890 million; and Galapagos NV to acquire CellPoint BV for a consideration of approximately $236.6 million were the three major deals that contributed 81.3 per cent of the total deal value during June 2022, the report said.

The industry reported 115 Venture Capital (VC) deals worth $3.7 billion in June 2022, compared to the last 12-month average (June 2021 to May 2022) of 161 deals worth $4.3 billion.

National Resilience Inc raising $625 million in series D round of financing to support its next phase of growth; Frontera Therapeutics raising $160 million in series B round of financing to test its first gene therapy trial; DOMA Pharmaceutical Technology (Suzhou) raising $142 million in series A round of financing to build an integrated platform for incubating innovative drugs were the major VC deals reported in June 2022, the report concluded.